TACIT (High Sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial)

dc.contributor.authorPang, Peter S.
dc.contributor.authorFermann, Gregory J.
dc.contributor.authorHunter, Benton R.
dc.contributor.authorLevy, Phillip D.
dc.contributor.authorLane, Kathleen A.
dc.contributor.authorLi, Xiaochun
dc.contributor.authorCole, Mette
dc.contributor.authorCollins, Sean P.
dc.contributor.departmentEmergency Medicine, School of Medicineen_US
dc.date.accessioned2021-01-27T21:15:21Z
dc.date.available2021-01-27T21:15:21Z
dc.date.issued2019-07-10
dc.description.abstractBackground Identifying low-risk acute heart failure (AHF) patients safe for discharge from the emergency department (ED) is a major unmet need. Methods A prospective, observational, multi-center pilot study targeting lower risk AHF patients to determine whether high sensitivity troponin T (hsTnT) identifies ED AHF patients at low risk for re-hospitalization and mortality. hsTnT was drawn at baseline and 3 hours. Phone follow up occurred at 30 and 90 days. The primary endpoint: composite of all-cause mortality, re-hospitalization, and ED visits at 90 days (changed from 30 days due to lack of mortality events), analyzed using logistic regression. Secondary endpoints: 30 and 90-day all-cause mortality. hsTnT values less than the 99th%ile were defined as ‘low’ hsTnT. Results Out of 527 enrolled patients, 499 comprised the initial analysis set. Of these, 332 had both 0 and 3-hour hsTnT drawn, of whom 319 completed 30 day follow up. The average age was 62, 60% male, and 57% Black. Median hsTnT was 26.4ng/L (IQR 15.1–44.3). There were 99 (21%) 30-day composite events, 13 (2.7%) deaths at 30 days and 25 deaths (8.2%) at 90 days. Serial hsTnT values below the 99th%ile were not associated with a lower risk for the 90-day primary composite endpoint (OR 0.79 (95% CI 0.42–1.50) p=0.4736). However, no deaths occurred in the low hsTnT group at 30 days with 1 death at 90 days. Conclusions hsTnT did not identify patients at low risk for the primary outcome of re-hospitalization, ED visits, and mortality at 90 days.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationPang Peter S., Fermann Gregory J., Hunter Benton R., Levy Phillip D., Lane Kathleen A., Li Xiaochun, Cole Mette, & Collins Sean P. (2019). TACIT (High Sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial). Circulation: Heart Failure, 12(7), e005931. https://doi.org/10.1161/CIRCHEARTFAILURE.119.005931en_US
dc.identifier.urihttps://hdl.handle.net/1805/25023
dc.publisherAmerican Heart Associationen_US
dc.relation.isversionof10.1161/CIRCHEARTFAILURE.119.005931en_US
dc.relation.journalCirculation: Heart Failureen_US
dc.sourcePMCen_US
dc.subjectBiomarkersen_US
dc.subjectHeart Failureen_US
dc.subjectTime Factorsen_US
dc.subjectacute heart failureen_US
dc.subjectemergency departmenten_US
dc.titleTACIT (High Sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial)en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms-1530207.pdf
Size:
759.32 KB
Format:
Adobe Portable Document Format
Description:
Author's manuscript
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: